Familial hemophagocytic lymphohistiocytosis: improved neurodevelopmental outcome after bone marrow transplantation

A Shuper1, D Attias, L Kornreich

  • 1National Center of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petab Tiqva, Israel.

Insights

Bone marrow transplantation (BMT) may reverse neurodevelopmental delays in children with familial hemophagocytic lymphohistiocytosis (HLH). This treatment showed positive outcomes in a young child with HLH, indicating potential for recovery.

Area of Science:

  • Pediatric Hematology
  • Neuroscience
  • Immunology

Background:

  • Familial hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening genetic disorder of immune dysregulation.
  • HLH can lead to severe multi-organ inflammation, including neurological complications like developmental delays and calcifications.

Observation:

  • A 5-month-old infant diagnosed with familial HLH presented with delayed psychomotor development and diffuse brain calcifications.
  • The child underwent allogeneic bone marrow transplantation (BMT) as a life-saving intervention.

Findings:

  • Following BMT, the child exhibited a gradual normalization of neurodevelopmental status.
  • Post-transplant imaging and clinical assessments indicated a reversal of the previously observed neurological deficits.

Implications:

  • Allogeneic bone marrow transplantation may offer a therapeutic window to reverse or mitigate neurodevelopmental deterioration in pediatric HLH.
  • These findings highlight the importance of considering BMT not only for HLH control but also for potential neurological recovery.